Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial

Fig. 1

Design of the RESTART trial. NSCLC, non–small cell lung cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; CCr, creatinine clearance; CNS, central nervous system; CBDCA, carboplatin; nab-PTX, nanoparticle albumin-bound paclitaxel; PD, progressive disease; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; DOR, duration of response

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us